Cerapedics is a passionate, customer-focused, research-based team dedicated to enhancing the science of bone repair by staying at the leading edge of osteobiologic science and product development.
ABOUT i-FACTOR Bone Graft
Our lead technology platform (i-FACTOR Peptide Enhanced Bone Graft) is the only biologic bone graft that uses a unique small peptide attachment factor (P-15) bound to anorganic bone mineral (ABM). This novel (P-15/ABM) combination acts as an attachment factor for osteogenic cells.
The first P-15 enhanced bone graft substitute was developed for use in the oral cavity by CeraMed Dental – the precursor to Cerapedics – under the leadership of Andrew J. Tofe, PhD. The product received PMA approval in 1999 based on the results of two prospective multi-center investigations. It remains the only dental bone graft substitute with FDA approved claims of superiority over demineralized bone matrix (DBM) allograft and alloplasts. Since approval, P-15/ABM has been used in an estimated 500,000 procedures.
From these roots, Cerapedics has reformulated the (P-15/ABM) product and branded it i-FACTOR Peptide Enhanced Bone Graft to capture the unique “attachment factor” mechanism of action. Cerapedics is now actively involved in introducing the i-FACTOR Bone Graft technology platform into the rapidly expanding market for osteobiologic products.